分组1 - Castle Biosciences, Inc. reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of a loss of $0.51 per share, representing an earnings surprise of +129.41% [1] - The company posted revenues of $86.19 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 16.64%, although this is a slight decrease from year-ago revenues of $87 million [2] - Castle Biosciences has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed the market, losing about 45% since the beginning of the year, while the S&P 500 has gained 6.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.63 on revenues of $66.56 million, and -$2.29 on revenues of $295.13 million for the current fiscal year [7] 分组3 - The Zacks Industry Rank indicates that the Medical - Biomedical and Genetics sector is currently in the bottom 43% of over 250 Zacks industries, suggesting potential underperformance compared to the top 50% of ranked industries [8] - The estimate revisions trend for Castle Biosciences was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]

Financial Performance - Lattice Semiconductor reported quarterly earnings of $0.24 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.23 per share a year ago [1] - The company posted revenues of $123.97 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.26%, but down from $124.08 million year-over-year [2] - Over the last four quarters, Lattice has not surpassed consensus EPS estimates, while it has topped consensus revenue estimates four times [2][3] Stock Performance and Outlook - Lattice shares have declined approximately 13.5% since the beginning of the year, contrasting with the S&P 500's gain of 6.1% [3] - The future performance of Lattice's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.27 on revenues of $130.98 million, and for the current fiscal year, it is $1.05 on revenues of $515.79 million [7] - The estimate revisions trend for Lattice was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Electronics - Semiconductors industry, to which Lattice belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - Krystal Biotech, Inc. reported quarterly earnings of $1.29 per share, exceeding the Zacks Consensus Estimate of $1.08 per share, and showing an increase from $0.86 per share a year ago, indicating a positive earnings surprise of +19.44% [1] Financial Performance - The company achieved revenues of $96.04 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.12%, and up from $70.28 million in the same quarter last year [2] - Over the last four quarters, Krystal Biotech has exceeded consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Since the beginning of the year, Krystal Biotech shares have increased by approximately 0.2%, while the S&P 500 has gained 6.1% [3] - The company's current consensus EPS estimate for the upcoming quarter is $1.24 on revenues of $100.9 million, and for the current fiscal year, it is $5.18 on revenues of $397.35 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Krystal Biotech belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Krystal Biotech's stock performance [5]

Core Insights - Energizer Holdings (ENR) reported quarterly earnings of $1.13 per share, significantly exceeding the Zacks Consensus Estimate of $0.61 per share, and up from $0.79 per share a year ago, representing an earnings surprise of +85.25% [1] - The company achieved revenues of $725.3 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.39% and increasing from $701.4 million year-over-year [2] - Energizer has outperformed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates twice in the same period [2] Future Outlook - The immediate price movement of Energizer's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.44 on revenues of $824.33 million, while the estimate for the current fiscal year is $3.40 on revenues of $2.92 billion [7] - The Zacks Rank for Energizer is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Consumer Products - Staples industry, to which Energizer belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Balchem (BCPC) reported quarterly earnings of $1.27 per share, exceeding the Zacks Consensus Estimate of $1.25 per share, and up from $0.98 per share a year ago, representing an earnings surprise of +1.60% [1] - The company posted revenues of $255.47 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.41%, compared to $234.08 million in the same quarter last year [2] - Over the last four quarters, Balchem has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] Market Outlook - Balchem shares have declined approximately 6.7% since the beginning of the year, while the S&P 500 has gained 8.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.36 on revenues of $261.58 million, and for the current fiscal year, it is $5.15 on revenues of $1.03 billion [7] Industry Context - The Chemical - Specialty industry, to which Balchem belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current status of estimate revisions for Balchem translates into a Zacks Rank 3 (Hold), suggesting the shares are expected to perform in line with the market in the near future [6]

Group 1 - The stock of Omnicell (OMCL) closed at $31.01, showing a 3.9% increase over the past four weeks, with a mean price target of $44.8 indicating a potential upside of 44.5% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $9.73, where the lowest estimate is $34.00 (9.6% increase) and the highest is $57.00 (83.8% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.9%, with one estimate moving higher and no negative revisions [12] - OMCL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does suggest a positive direction for price movement [14]

Core Viewpoint - iRadimed (IRMD) reported quarterly earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.45 per share, and showing an increase from $0.42 per share a year ago, indicating a positive earnings surprise of +8.89% [1] Group 1: Earnings Performance - The company achieved revenues of $20.41 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.49% and up from $17.93 million year-over-year [2] - Over the last four quarters, iRadimed has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - iRadimed shares have increased approximately 6.1% since the beginning of the year, while the S&P 500 has gained 7.8% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $0.44 for the upcoming quarter and $1.76 for the current fiscal year [7] Group 3: Industry Context - The Medical - Instruments industry, to which iRadimed belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Financial Performance - Dominion Energy reported quarterly earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.69 per share, and up from $0.55 per share a year ago, representing an earnings surprise of +8.70% [1] - The company posted revenues of $3.81 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.54%, compared to $3.49 billion in the same quarter last year [2] - Over the last four quarters, Dominion Energy has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - Dominion Energy shares have increased approximately 8.5% since the beginning of the year, outperforming the S&P 500's gain of 7.8% [3] - The current Zacks Rank for Dominion Energy is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.14 on revenues of $4.08 billion, and for the current fiscal year, it is $3.39 on revenues of $15.24 billion [7] - The outlook for the Utility - Electric Power industry is positive, currently ranking in the top 33% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Moderna (MRNA) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.99. This compares to a loss of $3.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +28.76%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.92 per share when it actually produced a loss of $2.52, delivering a surprise of +13.7%.Over the last four quarters, the company has ...

分组1 - LyondellBasell reported quarterly earnings of $0.62 per share, missing the Zacks Consensus Estimate of $0.87 per share, and down from $2.24 per share a year ago, representing an earnings surprise of -28.74% [1] - The company posted revenues of $7.66 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.41%, but down from $10.56 billion year-over-year [2] - LyondellBasell shares have declined approximately 22% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $1.16 on revenues of $7.34 billion, and for the current fiscal year, it is $3.50 on revenues of $29.79 billion [7] - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 5% of over 250 Zacks industries, indicating a challenging environment for the sector [8] - The estimate revisions trend for LyondellBasell was unfavorable ahead of the earnings release, resulting in a Zacks Rank 5 (Strong Sell) for the stock [6]